产品说明书
Oncrasin-1
 |
同义名 : | - |
| CAS号 : | 75629-57-1 | |
| 货号 : | A746103 | |
| 分子式 : | C16H12ClNO | |
| 纯度 : | 99%+ | |
| 分子量 : | 269.726 | |
| MDL号 : | MFCD01051808 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(389.28 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The oncogenic gene K-Ras mutations are frequently found in various cancers and are associated with resistance to treatment or poor prognosis. Oncrasin-1 is a potent and effective anticancer inhibitor against various lung cancer cells with K-Ras mutations at low or submicromolar concentrations. Oncrasin-1 induced dose-dependent cytotoxicity in T29Kt1 cells with an IC50 of 4.81 μM. Oncrasin-1 effectively killed K-Ras–mutant H460, H2122, H2887, and A549 cells with an IC50 of ≤3 μM. Oncrasin-1 (10 μM) effectively induced cell killing in T29Kt1 and H460 cells. Additionally, treatment of H460 cells with 1 μM oncrasin-1 effectively activated caspases 3 and 8. Oncrasin-1 (100 mg/kg/injection daily for 10 days) suppressed tumor growth by 75.4% in mice. Treatment with oncrasin-1 also prolonged survival: the mean survival times for mice treated with solvent and oncrasin-1 were 24 and 32, respectively, demonstrating that Oncrasin-1 might be useful for the treatment of cancers with K-Ras mutations[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.71mL 0.74mL 0.37mL |
18.54mL 3.71mL 1.85mL |
37.07mL 7.41mL 3.71mL |
| 参考文献 |
|---|